ArticleBMJ open2019
Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy.
Article in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Changes in Cost of Guideline-Concordant Cancer Treatment: Observations and Implications.JCO oncology practice · 2026Article
- Utilization and Determinants of Anticancer Drugs Under China's National Drug Price Negotiation Policy.Risk management and healthcare policy · 2025Article
- Variables affecting new drug prices in South Korea's pricing system.Frontiers in pharmacology · 2024Article
- Correlation of Anticancer Drug Prices with Outcomes of Overall Survival and Progression-Free Survival in Clinical Trials in Japan.Current oncology (Toronto, Ont.) · 2023Article
- Assessment of Price and Clinical Benefit of Cancer Drugs in Canada, 2011-2020.JAMA network open · 2023Article
- Reporting reimbursement price decisions for onco-hematology drugs in Spain.Frontiers in public health · 2023Article
- Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study.Journal of global health · 2022Article
- Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China.PharmacoEconomics · 2022Article
- A Proposal for Value-Based Managed Entry Agreements in an Environment of Technological Change and Economic Challenge for Publicly Funded Healthcare Systems.Frontiers in medical technology · 2022Article
- Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018.JAMA internal medicine · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate whether the prices of new anticancer drugs correlated with their relative benefit despite negotiation.
designRetrospective cross-sectional study correlating new anticancer drugs prices with clinical outcomes.
settingWe did a retrospective cross-sectional study including all new anticancer drugs approved by the European Medicines Agency (EMA) (2010-2016) and reimbursed in Italy. MAIN OUTCOMES AND MEASURES: Information on clinical outcomes-in terms of median overall survival (OS), median progression-free survival (PFS) and objective response rate (ORR)-was extracted from pivotal trials as reported in the European Public Assessment Reports available on the EMA website. Cost of a full course treatment was estimated on negotiated official and discounted prices. Regression coefficients β, their levels of significance p and the coefficients of determination R
resultsOverall, 30 new anticancer drugs (with 35 indications) were available for analysis. Where data on OS were available, we observed no correlation between the improvement in median OS (in weeks) and negotiated price (R CONCLUSIONS AND RELEVANCE: Our results suggest that the prices of anticancer drugs in Italy do not reflect their therapeutic benefit. Drug price negotiations, which is mandatory by law in Italy, do not seem to ensure that prices correlate with clinical benefits provided by the cancer drugs. These results call for further efforts to establish the standard determinants of drug prices available at the time of negotiation. These findings need to be confirmed in other countries where price negotiations are in place. Moreover, further investigations may verify whether outcome data obtained after drug marketing would improve the correlation between prices and therapeutic benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.